Importantly, since SGLT2 inhibitors achieve their glucose-lowering effect through an insulin-independent mechanism, they permit lower insulin requirements of subjects with T2DM and can be used effectively in any stage of T2DM (Vallon, 2015). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.